[TABLE OF CONTENTS]

1 INTRODUCTION OF GLOBAL PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS

2 EXECUTIVE SUMMARY: PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET

3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS

4 GLOBAL PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE

5 GLOBAL PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE
5.1 OVERVIEW
5.2 CHROMOSOMAL ABNORMALITIES
5.3 ANEUPLOIDY
5.4 X-LINKED DISEASES
5.5 SINGLE GENE DISORDERS
5.6 HLA TYPING
5.7 GENDER SELECTION
5.8 OTHERS

6 GLOBAL PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY GEOGRAPHY
6.1 OVERVIEW

6.2 NORTH AMERICA

6.2.1 NORTH AMERICA MARKET SNAPSHOT
6.2.2 U.S.
6.2.3 CANADA
6.2.4 MEXICO

6.3 EUROPE

6.3.1 EUROPE MARKET SNAPSHOT
6.3.2 WESTERN EUROPE
6.3.2.1 THE UK
6.3.2.2 GERMANY
6.3.2.3 FRANCE
6.3.2.4 ITALY
6.3.2.5 SPAIN
6.3.2.6 REST OF WESTERN EUROPE
6.3.3 EASTERN EUROPE
6.3.3.1 POLAND
6.3.3.2 RUSSIA
6.3.3.3 REST OF EASTERN EUROPE

6.4 ASIA PACIFIC

6.4.1 ASIA PACIFIC MARKET SNAPSHOT
6.4.2 CHINA
6.4.3 JAPAN
6.4.4 INDIA
6.4.5 AUSTRALIA & NEW ZEALAND
6.4.6 ASEAN
6.4.7 REST OF ASIA PACIFIC

6.5 MIDDLE EAST & AFRICA

6.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
6.5.2 UAE
6.5.3 SAUDI ARABIA
6.5.4 SOUTH AFRICA
6.5.5 REST OF MEA

6.6 SOUTH AMERICA

6.6.1 SOUTH AMERICA MARKET SNAPSHOT
6.6.2 BRAZIL
6.6.3 ARGENTINA
6.6.4 REST OF SOUTH AMERICA

7 GLOBAL PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET COMPETITIVE LANDSCAPE
7.1 OVERVIEW
7.2 COMPANY MARKET RANKING
7.3 KEY DEVELOPMENT STRATEGIES
7.4 COMPETITIVE DASHBOARD
7.5 PRODUCT MAPPING
7.6 TOP PLAYER POSITIONING, 2022
7.7 COMPETITIVE HEATMAP
7.8 TOP WINNING STRATEGIES

8 COMPANY PROFILES

8.1 REPRODUCTIVE GENETIC INNOVATIONS (RGI)
8.1.1 OVERVIEW
8.1.2 FINANCIAL PERFORMANCE
8.1.3 PRODUCT OUTLOOK
8.1.4 KEY DEVELOPMENTS
8.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.2 AGILENT TECHNOLOGIES
8.2.1 OVERVIEW
8.2.2 FINANCIAL PERFORMANCE
8.2.3 PRODUCT OUTLOOK
8.2.4 KEY DEVELOPMENTS
8.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.3 QUEST DIAGNOSTICS
8.3.1 OVERVIEW
8.3.2 FINANCIAL PERFORMANCE
8.3.3 PRODUCT OUTLOOK
8.3.4 KEY DEVELOPMENTS
8.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.4 INVITAE CORPORATION
8.4.1 OVERVIEW
8.4.2 FINANCIAL PERFORMANCE
8.4.3 PRODUCT OUTLOOK
8.4.4 KEY DEVELOPMENTS
8.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.5 PERKINELMER
8.5.1 OVERVIEW
8.5.2 FINANCIAL PERFORMANCE
8.5.3 PRODUCT OUTLOOK
8.5.4 KEY DEVELOPMENTS
8.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.6 LABORATORY CORPORATION OF AMERICA HOLDINGS
8.6.1 OVERVIEW
8.6.2 FINANCIAL PERFORMANCE
8.6.3 PRODUCT OUTLOOK
8.6.4 KEY DEVELOPMENTS
8.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.7 ILLUMINA INC
8.7.1 OVERVIEW
8.7.2 FINANCIAL PERFORMANCE
8.7.3 PRODUCT OUTLOOK
8.7.4 KEY DEVELOPMENTS
8.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.8 CEGAT GMBH
8.8.1 OVERVIEW
8.8.2 FINANCIAL PERFORMANCE
8.8.3 PRODUCT OUTLOOK
8.8.4 KEY DEVELOPMENTS
8.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.9 PACGENOMICS
8.9.1 OVERVIEW
8.9.2 FINANCIAL PERFORMANCE
8.9.3 PRODUCT OUTLOOK
8.9.4 KEY DEVELOPMENTS
8.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS

8.10 NATERA INC
8.10.1 OVERVIEW
8.10.2 FINANCIAL PERFORMANCE
8.10.3 PRODUCT OUTLOOK
8.10.4 KEY DEVELOPMENTS
8.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS